MARKER THERAPEUTICS (MRKR)
(Delayed Data from NSDQ)
$5.40 USD
+0.56 (11.57%)
Updated Jul 24, 2024 03:59 PM ET
After-Market: $5.53 +0.13 (2.41%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MRKR 5.40 +0.56(11.57%)
Will MRKR be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MRKR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MRKR
MARKER THERAPEUTICS, INC. (MRKR) Reports Q3 Loss, Tops Revenue Estimates
MRKR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for MRKR
MRKR Stock Earnings: Marker Therapeutics Reported Results for Q4 2023
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
MRKR Stock Earnings: Marker Therapeutics Reported Results for Q1 2024
Marker Therapeutics’ Promising Cancer Therapy Progress